FLGT

SEC source: 0001209191-23-027775 · doc4.xml · nonDerivative · entry 1

Xie Jian · CIK 0001819718 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 428,547

F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 3, 2020, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2020.

SEC source: 0001209191-23-027768 · doc4.xml · nonDerivative · entry 1

Kim Paul · CIK 0001253820 · CFO and Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 231,559

F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 3, 2020, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2020.

SEC source: 0001209191-23-027090 · doc4.xml · nonDerivative · entry 1

Xie Jian · CIK 0001819718 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 434,745

F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019.

SEC source: 0001209191-23-026560 · doc4.xml · nonDerivative · entry 1

Gao Hanlin · CIK 0001684532 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 915,736

F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on April 30, 2021, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on May 3, 2021.

SEC source: 0001209191-23-015564 · doc4.xml · nonDerivative · entry 1

Xie Jian · CIK 0001819718 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 435,520

F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022.

SEC source: 0001209191-23-015514 · doc4.xml · nonDerivative · entry 1

Gao Hanlin · CIK 0001684532 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 915,812

F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022.

SEC source: 0001209191-23-015542 · doc4.xml · nonDerivative · entry 2

KIM PAUL · CIK 0001253820 · CFO and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 232,424

F2 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022.

SEC source: 0001209191-23-015542 · doc4.xml · nonDerivative · entry 1

KIM PAUL · CIK 0001253820 · CFO and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 236,229

F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 27, 2019, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 4, 2019.

SEC source: 0001209191-23-014113 · doc4.xml · nonDerivative · entry 1

Xie Jian · CIK 0001819718 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 439,565

F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 27, 2019.

SEC source: 0001209191-23-013297 · doc4.xml · nonDerivative · entry 3

Xie Jian · CIK 0001819718 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 439,998

F3 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 28, 2022.

SEC source: 0001209191-23-013297 · doc4.xml · nonDerivative · entry 2

Xie Jian · CIK 0001819718 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 440,739

F2 · shares: Restricted stock units. The shares subject to the restricted stock units vest over a period of three years, with 1/3rd of such shares vesting 12 months after February 23, 2023, and 1/12th of such shares vesting at the end of every three month period thereafter over the remaining 24 months, subject to continued service for Issuer on each vesting date.

SEC source: 0001209191-23-013297 · doc4.xml · nonDerivative · entry 1

Xie Jian · CIK 0001819718 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 426,166

F1 · shares: Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 28, 2022.

SEC source: 0001209191-23-013280 · doc4.xml · nonDerivative · entry 3

Gao Hanlin · CIK 0001684532 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 919,616

F3 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 28, 2022.

SEC source: 0001209191-23-013280 · doc4.xml · nonDerivative · entry 2

Gao Hanlin · CIK 0001684532 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 920,410

F2 · shares: Restricted stock units. The shares subject to the restricted stock units vest over a period of three years, with 1/3rd of such shares vesting 12 months after February 23, 2023, and 1/12th of such shares vesting at the end of every three-month period thereafter over the remaining 24 months, subject to continued service for Issuer on each vesting date.

SEC source: 0001209191-23-013280 · doc4.xml · nonDerivative · entry 1

Gao Hanlin · CIK 0001684532 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 908,254

F1 · shares: Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 28, 2022.

SEC source: 0001209191-23-013290 · doc4.xml · nonDerivative · entry 3

KIM PAUL · CIK 0001253820 · CFO and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 236,662

F3 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 28, 2022.

SEC source: 0001209191-23-013290 · doc4.xml · nonDerivative · entry 2

KIM PAUL · CIK 0001253820 · CFO and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 237,403

F2 · shares: Restricted stock units. The shares subject to the restricted stock units vest over a period of three years, with 1/3rd of such shares vesting 12 months after February 23, 2023, and 1/12th of such shares vesting at the end of every three month period thereafter over the remaining 24 months, subject to continued service for Issuer on each vesting date.

SEC source: 0001209191-23-013290 · doc4.xml · nonDerivative · entry 1

KIM PAUL · CIK 0001253820 · CFO and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 223,185

F1 · shares: Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 28, 2022.

SEC source: 0001209191-23-013286 · doc4.xml · nonDerivative · entry 3

Hsieh Ming · CIK 0001302110 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 648,555

F3 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 28, 2022.

SEC source: 0001209191-23-013286 · doc4.xml · nonDerivative · entry 2

Hsieh Ming · CIK 0001302110 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 651,180

F2 · shares: Restricted stock units. The shares subject to the restricted stock units vest over a period of three years, with 1/3rd of such shares vesting 12 months after February 23, 2023, and 1/12th of such shares vesting at the end of every three month period thereafter over the remaining 24 months, subject to continued service for Issuer on each vesting date.

SEC source: 0001209191-23-013286 · doc4.xml · nonDerivative · entry 1

Hsieh Ming · CIK 0001302110 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 603,787

F1 · shares: Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on August 1, 2022.

SEC source: 0001209191-23-010753 · doc4.xml · nonDerivative · entry 1

Xie Jian · CIK 0001819718 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 424,024

F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on November 1, 2019.

SEC source: 0001209191-23-010727 · doc4.xml · nonDerivative · entry 1

Gao Hanlin · CIK 0001684532 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 906,112

F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2019.

SEC source: 0001209191-23-010744 · doc4.xml · nonDerivative · entry 2

KIM PAUL · CIK 0001253820 · CFO and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 221,043

F2 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on November 1, 2019, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 5, 2019.

SEC source: 0001209191-23-010744 · doc4.xml · nonDerivative · entry 1

KIM PAUL · CIK 0001253820 · CFO and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 222,062

F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2019.

SEC source: 0001209191-23-007608 · doc4.xml · nonDerivative · entry 1

Xie Jian · CIK 0001819718 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 425,042

F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 3, 2020, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2020.

SEC source: 0001209191-23-007605 · doc4.xml · nonDerivative · entry 1

KIM PAUL · CIK 0001253820 · CFO and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 222,383

F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 3, 2020, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2020.

SEC source: 0001209191-23-006860 · doc4.xml · nonDerivative · entry 1

Xie Jian · CIK 0001819718 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 429,450

F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019.

SEC source: 0001209191-23-005984 · doc4.xml · nonDerivative · entry 1

Gao Hanlin · CIK 0001684532 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 906,495

F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on April 30, 2021, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on May 3, 2021.

SEC source: 0001209191-23-000986 · doc4.xml · derivative · entry 2

GROVES REGINA E · CIK 0001653877 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2033-01-02

F2 · derivative.exercise_date: The shares subject to the option vest over a period of four years, with 1/4th of such shares vesting 12 months after January 3, 2023, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to the reporting person's continued service for Issuer on each vesting date.

SEC source: 0001209191-23-000986 · doc4.xml · nonDerivative · entry 1

GROVES REGINA E · CIK 0001653877 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,000

F1 · shares: Restricted stock units. The shares subject to the restricted stock units vest over a period of four years, with 1/4th of such shares vesting 12 months after January 3, 2023, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to the reporting person's continued service for Issuer on each vesting date.

SEC source: 0001209191-22-060015 · doc4.xml · nonDerivative · entry 1

KIM PAUL · CIK 0001253820 · CFO and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 223,403

F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 27, 2019, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 4, 2019.

F2 · price: The shares were sold in multiple transactions at prices ranging from $34.86 to $35.98, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001209191-22-059453 · doc4.xml · nonDerivative · entry 1

Xie Jian · CIK 0001819718 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 430,074

F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 27, 2019.

F2 · price: The shares were sold in multiple transactions at prices ranging from $34.0900 to $35.2750, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001209191-22-057844 · doc4.xml · nonDerivative · entry 1

Xie Jian · CIK 0001819718 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 430,759

F1 · shares: The shares were sold from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on November 1, 2019.

F2 · price: The shares were sold in multiple transactions at prices ranging from $35.515 to $36.370, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001209191-22-057840 · doc4.xml · nonDerivative · entry 1

Gao Hanlin · CIK 0001684532 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 906,585

F1 · shares: The shares were sold from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2019.

F2 · price: The shares were sold in multiple transactions at prices ranging from $35.515 to $36.370, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001209191-22-057841 · doc4.xml · nonDerivative · entry 2

KIM PAUL · CIK 0001253820 · CFO and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 224,056

F3 · shares: The shares were sold from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2019.

F2 · price: The shares were sold in multiple transactions at prices ranging from $35.515 to $36.370, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001209191-22-057841 · doc4.xml · nonDerivative · entry 1

KIM PAUL · CIK 0001253820 · CFO and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 224,546

F1 · shares: The shares were sold from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on November 1, 2019, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 5, 2019.

F2 · price: The shares were sold in multiple transactions at prices ranging from $35.515 to $36.370, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001209191-22-056317 · doc4.xml · nonDerivative · entry 2

Xie Jian · CIK 0001819718 · President and COO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 220,816

F3 · kind: At the effective time of the Merger, each issued and outstanding share of Fulgent Pharma preferred stock was converted into 0.02314 shares of Fulgent Genetics common stock, par value $0.0001 per share. Of the 220,816 shares of common stock issued to Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Dynasty Trust") in connection with the Merger, of which 104,098 shares are currently being held in escrow and following the expiration of the indemnification periods set forth in the Merger Agreement, shall be issued pro rata to the Trust in accordance with the terms of the Merger Agreement.

F4 · ownership.nature: Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust. Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein.

SEC source: 0001209191-22-056317 · doc4.xml · nonDerivative · entry 1

Xie Jian · CIK 0001819718 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 432,065

F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 (the "Merger Agreement") by and among Fulgent Genetics, Inc. ("Fulgent Genetics"), FG Merger Sub, Inc. ("FG"), Fulgent Pharma Holdings, Inc. ("Fulgent Pharma"), and the stockholders listed therein, FG merged with and into Fulgent Pharma (the "Merger"), with Fulgent Pharma being the surviving corporation following the Merger. At the effective time of the Merger (the "Effective Time"), each award of restricted stock units ("RSUs") based on Fulgent Pharma common stock that was outstanding immediately prior to the Effective Time ("Fulgent Pharma RSUs") was assumed and converted into the right to receive RSUs based on the common stock of Fulgent Genetics with the same terms and conditions as the Fulgent Pharma RSUs immediately prior to the Effective Time, subject to the applicable exchange ratio.

F2 · kind: (continued from footnote 1) Twenty-five percent (25%) of the shares subject to RSUs reported herein will vest on the first anniversary of the date of the award, October 26, 2022, and 1/16th of the shares will vest every three months over the remaining 36-month period, subject to continued service for Issuer on each vesting date.

SEC source: 0001209191-22-056316 · doc4.xml · nonDerivative · entry 1

Gao Hanlin · CIK 0001684532 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 906,927

F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 (the "Merger Agreement") by and among Fulgent Genetics, Inc. ("Fulgent Genetics"), FG Merger Sub, Inc. ("FG"), Fulgent Pharma Holdings, Inc. ("Fulgent Pharma"), and the stockholders listed therein, FG merged with and into Fulgent Pharma (the "Merger"), with Fulgent Pharma being the surviving corporation following the Merger. At the effective time of the Merger (the "Effective Time"), each award of restricted stock units ("RSUs") based on Fulgent Pharma common stock that was outstanding immediately prior to the Effective Time ("Fulgent Pharma RSUs") was assumed and converted into the right to receive RSUs based on the common stock of Fulgent Genetics with the same terms and conditions as the Fulgent Pharma RSUs immediately prior to the Effective Time, subject to the applicable exchange ratio.

F2 · kind: (continued from footnote 1) Twenty-five percent (25%) of the shares subject to RSUs reported herein will vest on the first anniversary of the date of the award, October 26, 2022, and 1/16th of the shares will vest every three months over the remaining 36-month period, subject to continued service for Issuer on each vesting date.

SEC source: 0001209191-22-056319 · doc4.xml · nonDerivative · entry 1

KIM PAUL · CIK 0001253820 · CFO and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 225,852

F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 (the "Merger Agreement") by and among Fulgent Genetics, Inc. ("Fulgent Genetics"), FG Merger Sub, Inc. ("FG"), Fulgent Pharma Holdings, Inc. ("Fulgent Pharma"), and the stockholders listed therein, FG merged with and into Fulgent Pharma (the "Merger"), with Fulgent Pharma being the surviving corporation following the Merger. At the effective time of the Merger (the "Effective Time"), each award of restricted stock units ("RSUs") based on Fulgent Pharma common stock that was outstanding immediately prior to the Effective Time ("Fulgent Pharma RSUs") was assumed and converted into the right to receive RSUs based on the common stock of Fulgent Genetics with the same terms and conditions as the Fulgent Pharma RSUs immediately prior to the Effective Time, subject to the applicable exchange ratio.

F2 · kind: (continued from footnote 1) Twenty-five percent (25%) of the shares subject to RSUs reported herein will vest on the first anniversary of the date of the award, October 26, 2022, and 1/16th of the shares will vest every three months over the remaining 36-month period, subject to continued service for Issuer on each vesting date.

SEC source: 0001209191-22-056318 · doc4.xml · nonDerivative · entry 2

Hsieh Ming · CIK 0001302110 · Director · Chief Executive Officer · 10% owner

Ming Hsieh Trust · CIK 0001836339 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 220,816

F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 (the "Merger Agreement") by and among Fulgent Genetics, Inc. ("Fulgent Genetics"), FG Merger Sub, Inc. ("FG"), Fulgent Pharma Holdings, Inc. ("Fulgent Pharma"), and the stockholders listed therein, FG merged with and into Fulgent Pharma (the "Merger"), with Fulgent Pharma being the surviving corporation following the Merger. At the effective time of the Merger, each issued and outstanding share of Fulgent Pharma preferred stock was converted into 0.02314 shares of Fulgent Genetics common stock, par value $0.0001 per share.

F2 · kind: (continued from footnote 1) Of the 566,171 shares of common stock issued to Mr. Hsieh and 220,816 shares of common stock issued to The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Dynasty Trust") in connection with the Merger, of which 266,908 and 104,098 shares, respectively, are currently being held in escrow and following the expiration of the indemnification periods set forth in the Merger Agreement, shall be issued pro rata to Mr. Hsieh and the Trust in accordance with the terms of the Merger Agreement.

F3 · ownership.nature: Securities held by the Dynasty Trust. Mr. Hsieh is the grantor of the Dynasty Trust and he and his spouse, Eva Hsieh, and Jian Xie serve on the investment committee of the Dynasty Trust. Mr. Hsieh disclaims any beneficial interest except with respect to any pecuniary interest therein.

SEC source: 0001209191-22-056318 · doc4.xml · nonDerivative · entry 1

Hsieh Ming · CIK 0001302110 · Director · Chief Executive Officer · 10% owner

Ming Hsieh Trust · CIK 0001836339 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 596,171

F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 (the "Merger Agreement") by and among Fulgent Genetics, Inc. ("Fulgent Genetics"), FG Merger Sub, Inc. ("FG"), Fulgent Pharma Holdings, Inc. ("Fulgent Pharma"), and the stockholders listed therein, FG merged with and into Fulgent Pharma (the "Merger"), with Fulgent Pharma being the surviving corporation following the Merger. At the effective time of the Merger, each issued and outstanding share of Fulgent Pharma preferred stock was converted into 0.02314 shares of Fulgent Genetics common stock, par value $0.0001 per share.

F2 · kind: (continued from footnote 1) Of the 566,171 shares of common stock issued to Mr. Hsieh and 220,816 shares of common stock issued to The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Dynasty Trust") in connection with the Merger, of which 266,908 and 104,098 shares, respectively, are currently being held in escrow and following the expiration of the indemnification periods set forth in the Merger Agreement, shall be issued pro rata to Mr. Hsieh and the Trust in accordance with the terms of the Merger Agreement.

SEC source: 0001209191-22-055974 · doc4.xml · nonDerivative · entry 1

Xie Jian · CIK 0001819718 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 302,756

F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 3, 2020, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2020.

SEC source: 0001209191-22-055970 · doc4.xml · nonDerivative · entry 1

KIM PAUL · CIK 0001253820 · CFO and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 148,267

F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 3, 2020, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2020.

SEC source: 0001209191-22-055527 · doc4.xml · nonDerivative · entry 1

Xie Jian · CIK 0001819718 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 308,954

F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019.

SEC source: 0001209191-22-055074 · doc4.xml · nonDerivative · entry 1

Gao Hanlin · CIK 0001684532 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 855,204

F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on April 30, 2021, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on May 3, 2021.

SEC source: 0001209191-22-050405 · doc4.xml · derivative · entry 5

Hsieh Ming · CIK 0001302110 · Director · Chief Executive Officer · 10% owner

Ming Hsieh Trust · CIK 0001836339 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 800,000

Underlying: Common Stock · 800,000 shares

Expires 2026-09-01

F4 · derivative.exercise_price: On September 14, 2022, the Trust entered into a master confirmation in respect of a prepaid variable forward agreement (the "Agreement") with an unaffiliated bank (the "Bank") relating to 800,000 shares of Common Stock and obligating the Trust to deliver to the Bank up to 800,000 shares of Common Stock (or, at the Trust's election, an equivalent amount of cash) to settle the Agreement.

F5 · derivative.exercise_price: In exchange for entering into the Agreement and assuming the obligations thereunder, the Trust received a cash payment of $28,955,274.40. The Trust pledged 800,000 shares of Common Stock (the "Pledged Shares") to secure its obligations under the Agreement, and retained voting rights in the Pledged Shares during the term of the pledge (and thereafter if the Trust settles the Agreement in cash).

F6 · derivative.exercise_price: Under the Agreement, on each of the eight settlement dates in September 2026, the Trust will be obligated to deliver to the Bank a number of shares of Common Stock determined as follows (or, at the Trust's election, an equivalent amount of cash): (a) if the closing price of the Common Stock on the related valuation date (the "Settlement Price") is less than or equal to $41.0261 (the "Floor Price"), the Trust will deliver to the Bank 100,000 shares (i.e., the ratable portion of the Pledged Shares to be delivered with respect to each settlement date).

F7 · derivative.exercise_price: (continued from footnote 6) (b) if the Settlement Price is between the Floor Price and $55.1572 (the "Cap Price"), the Trust will deliver to the Bank a number of shares of Common Stock equal to 100,000 shares multiplied by a fraction, the numerator of which is the Floor Price and the denominator of which is the Settlement Price: and (c) if the Settlement Price is greater than the Cap Price, the Trust will deliver to the Bank the number of shares of Common Stock equal to the product of (i) 100,000 shares and (ii) a fraction (a) the numerator of which is the sum of (x) the Floor Price and (y) the Settlement Price minus the Cap Price, and (b) the denominator of which is the Settlement Price.

F4 · kind: On September 14, 2022, the Trust entered into a master confirmation in respect of a prepaid variable forward agreement (the "Agreement") with an unaffiliated bank (the "Bank") relating to 800,000 shares of Common Stock and obligating the Trust to deliver to the Bank up to 800,000 shares of Common Stock (or, at the Trust's election, an equivalent amount of cash) to settle the Agreement.

F5 · kind: In exchange for entering into the Agreement and assuming the obligations thereunder, the Trust received a cash payment of $28,955,274.40. The Trust pledged 800,000 shares of Common Stock (the "Pledged Shares") to secure its obligations under the Agreement, and retained voting rights in the Pledged Shares during the term of the pledge (and thereafter if the Trust settles the Agreement in cash).

F6 · kind: Under the Agreement, on each of the eight settlement dates in September 2026, the Trust will be obligated to deliver to the Bank a number of shares of Common Stock determined as follows (or, at the Trust's election, an equivalent amount of cash): (a) if the closing price of the Common Stock on the related valuation date (the "Settlement Price") is less than or equal to $41.0261 (the "Floor Price"), the Trust will deliver to the Bank 100,000 shares (i.e., the ratable portion of the Pledged Shares to be delivered with respect to each settlement date).

F7 · kind: (continued from footnote 6) (b) if the Settlement Price is between the Floor Price and $55.1572 (the "Cap Price"), the Trust will deliver to the Bank a number of shares of Common Stock equal to 100,000 shares multiplied by a fraction, the numerator of which is the Floor Price and the denominator of which is the Settlement Price: and (c) if the Settlement Price is greater than the Cap Price, the Trust will deliver to the Bank the number of shares of Common Stock equal to the product of (i) 100,000 shares and (ii) a fraction (a) the numerator of which is the sum of (x) the Floor Price and (y) the Settlement Price minus the Cap Price, and (b) the denominator of which is the Settlement Price.

F4 · price: On September 14, 2022, the Trust entered into a master confirmation in respect of a prepaid variable forward agreement (the "Agreement") with an unaffiliated bank (the "Bank") relating to 800,000 shares of Common Stock and obligating the Trust to deliver to the Bank up to 800,000 shares of Common Stock (or, at the Trust's election, an equivalent amount of cash) to settle the Agreement.

F5 · price: In exchange for entering into the Agreement and assuming the obligations thereunder, the Trust received a cash payment of $28,955,274.40. The Trust pledged 800,000 shares of Common Stock (the "Pledged Shares") to secure its obligations under the Agreement, and retained voting rights in the Pledged Shares during the term of the pledge (and thereafter if the Trust settles the Agreement in cash).

F6 · price: Under the Agreement, on each of the eight settlement dates in September 2026, the Trust will be obligated to deliver to the Bank a number of shares of Common Stock determined as follows (or, at the Trust's election, an equivalent amount of cash): (a) if the closing price of the Common Stock on the related valuation date (the "Settlement Price") is less than or equal to $41.0261 (the "Floor Price"), the Trust will deliver to the Bank 100,000 shares (i.e., the ratable portion of the Pledged Shares to be delivered with respect to each settlement date).

F7 · price: (continued from footnote 6) (b) if the Settlement Price is between the Floor Price and $55.1572 (the "Cap Price"), the Trust will deliver to the Bank a number of shares of Common Stock equal to 100,000 shares multiplied by a fraction, the numerator of which is the Floor Price and the denominator of which is the Settlement Price: and (c) if the Settlement Price is greater than the Cap Price, the Trust will deliver to the Bank the number of shares of Common Stock equal to the product of (i) 100,000 shares and (ii) a fraction (a) the numerator of which is the sum of (x) the Floor Price and (y) the Settlement Price minus the Cap Price, and (b) the denominator of which is the Settlement Price.

F4 · derivative.exercise_date: On September 14, 2022, the Trust entered into a master confirmation in respect of a prepaid variable forward agreement (the "Agreement") with an unaffiliated bank (the "Bank") relating to 800,000 shares of Common Stock and obligating the Trust to deliver to the Bank up to 800,000 shares of Common Stock (or, at the Trust's election, an equivalent amount of cash) to settle the Agreement.

F5 · derivative.exercise_date: In exchange for entering into the Agreement and assuming the obligations thereunder, the Trust received a cash payment of $28,955,274.40. The Trust pledged 800,000 shares of Common Stock (the "Pledged Shares") to secure its obligations under the Agreement, and retained voting rights in the Pledged Shares during the term of the pledge (and thereafter if the Trust settles the Agreement in cash).

F6 · derivative.exercise_date: Under the Agreement, on each of the eight settlement dates in September 2026, the Trust will be obligated to deliver to the Bank a number of shares of Common Stock determined as follows (or, at the Trust's election, an equivalent amount of cash): (a) if the closing price of the Common Stock on the related valuation date (the "Settlement Price") is less than or equal to $41.0261 (the "Floor Price"), the Trust will deliver to the Bank 100,000 shares (i.e., the ratable portion of the Pledged Shares to be delivered with respect to each settlement date).

F7 · derivative.exercise_date: (continued from footnote 6) (b) if the Settlement Price is between the Floor Price and $55.1572 (the "Cap Price"), the Trust will deliver to the Bank a number of shares of Common Stock equal to 100,000 shares multiplied by a fraction, the numerator of which is the Floor Price and the denominator of which is the Settlement Price: and (c) if the Settlement Price is greater than the Cap Price, the Trust will deliver to the Bank the number of shares of Common Stock equal to the product of (i) 100,000 shares and (ii) a fraction (a) the numerator of which is the sum of (x) the Floor Price and (y) the Settlement Price minus the Cap Price, and (b) the denominator of which is the Settlement Price.

F1 · ownership.nature: Securities held by The Ming Hsieh Trust. Mr. Hsieh is the trustee of The Ming Hsieh Trust (the "Trust") and possesses the sole voting and dispositive power with respect to securities held by the Trust.

F4 · ownership.nature: On September 14, 2022, the Trust entered into a master confirmation in respect of a prepaid variable forward agreement (the "Agreement") with an unaffiliated bank (the "Bank") relating to 800,000 shares of Common Stock and obligating the Trust to deliver to the Bank up to 800,000 shares of Common Stock (or, at the Trust's election, an equivalent amount of cash) to settle the Agreement.

F5 · ownership.nature: In exchange for entering into the Agreement and assuming the obligations thereunder, the Trust received a cash payment of $28,955,274.40. The Trust pledged 800,000 shares of Common Stock (the "Pledged Shares") to secure its obligations under the Agreement, and retained voting rights in the Pledged Shares during the term of the pledge (and thereafter if the Trust settles the Agreement in cash).

F6 · ownership.nature: Under the Agreement, on each of the eight settlement dates in September 2026, the Trust will be obligated to deliver to the Bank a number of shares of Common Stock determined as follows (or, at the Trust's election, an equivalent amount of cash): (a) if the closing price of the Common Stock on the related valuation date (the "Settlement Price") is less than or equal to $41.0261 (the "Floor Price"), the Trust will deliver to the Bank 100,000 shares (i.e., the ratable portion of the Pledged Shares to be delivered with respect to each settlement date).

F7 · ownership.nature: (continued from footnote 6) (b) if the Settlement Price is between the Floor Price and $55.1572 (the "Cap Price"), the Trust will deliver to the Bank a number of shares of Common Stock equal to 100,000 shares multiplied by a fraction, the numerator of which is the Floor Price and the denominator of which is the Settlement Price: and (c) if the Settlement Price is greater than the Cap Price, the Trust will deliver to the Bank the number of shares of Common Stock equal to the product of (i) 100,000 shares and (ii) a fraction (a) the numerator of which is the sum of (x) the Floor Price and (y) the Settlement Price minus the Cap Price, and (b) the denominator of which is the Settlement Price.

SEC source: 0001209191-22-049195 · doc4.xml · nonDerivative · entry 1

KIM PAUL · CIK 0001253820 · CFO and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 149,507

F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 27, 2019.

F2 · price: The shares were sold in multiple transactions at prices ranging from $41.09 to $41.90, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

SEC source: 0001209191-22-048269 · doc4.xml · nonDerivative · entry 1

Xie Jian · CIK 0001819718 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 309,729

F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 27, 2019.

F2 · price: The shares were sold in multiple transactions at prices ranging from $43.90 to $44.93, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.